The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index; 19 of the 79 sources its claims cite were checked for support.
Abstract
The fine line between human health and disease can be driven by the interplay between host and microbial factors. This “metagenome” regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
13 Valid · 0 Not valid · 43 Not checked · 11 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“16S ribosomal RNA (rRNA)-based sequencing of gene amplicons and shotgun DNA sequencing of patient stool samples have identified subsets of bacteria more abundant in responding versus nonresponding patients.”
What the sources say
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
The patient-stool analysis and Fig. 4 caption (page unavailable in our copy) identify bacterial clusters with differing Bacteroides abundance, and the paper reports 16S rRNA gene-amplicon sequencing of feces. But the treatment-response comparison was between mice receiving stool from different patient clusters, not responding versus nonresponding patients; our copy also does not report shotgun DNA sequencing of patient stool. (LLM, conf=0.87)
- Not checked yetcites [14] source
- Partly supportedcites [15] sourceExperimental — accuracy not yet measured
The indexed passage labeled Abstract (page not supplied) reports 16S rRNA sequencing of mouse fecal samples and identifies Bifidobacterium as associated with stronger antitumor responses. It does not report shotgun DNA sequencing or a comparison of responding and nonresponding patients; a later passage proposes sequencing patient stool as future work. (LLM, conf=0.88)
- Not checked yetcites [18] source
- Not checked yetcites [19]
- Supportedcites [20] source
The supplied passages (labelled Abstract; page not provided) describe 16S rRNA gene amplicon sequencing and metagenomic shotgun sequencing of patient stool samples. They report bacterial species differentially enriched in responders and nonresponders, including eight more abundant in responders. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Accordingly, B. fragilis and Burkholderia cepacia administered via gavage to mice reduced the severity of colitis induced by mAb to CTLA-4 (13,22).”
What the sources say
- Supportedcites [13] source
The passage labeled Abstract (discussion of Fig. 3A; page not provided) reports that reconstituting antibiotic-treated mice with a combination of B. fragilis and B. cepacia reduced histopathological signs of colitis induced by CTLA-4 blockade. The Fig. 3 caption describes oral gavage and assessment of colonic lesions in those mice. (LLM, conf=0.94)
- Could not verifycites [22] sourceExperimental — accuracy not yet measured
The Results section, “Members of Bacteroidetes phylum associated with resistance” (page unavailable), reports an association between Bacteroidetes abundance and resistance to colitis in melanoma patients. Our copy does not address whether gavage with B. fragilis and Burkholderia cepacia reduced colitis severity in mice; searches for both species and for mouse gavage found no such passage. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In patients with metastatic melanoma treated with the checkpoint inhibitor ipilimumab (antibody to CTLA-4), the abundance of Bacteroidetes inversely correlated with the severity of colitis (22).”
What the sources say
- Supportedcites [22] source
The Results section (‘Members of Bacteroidetes phylum associated with resistance’; page not provided) says the authors stratified patients by inflammation severity and found Bacteroidetes more abundant in colitis-free patients. The Methods identify the patients as adults with metastatic melanoma who received ipilimumab. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a study performed in 541 patients with hematologic malignancies reported that the gut microbiome at diagnosis influenced the probability of relapse within 2 years after ASCT.”
What the sources say
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
The Methods and Results (page not provided) describe 541 patients with hematologic malignancies and assess microbiota associations with relapse or disease progression over two years. But the study concerns allogeneic HCT, not ASCT; its main cohort had stool samples collected within three weeks after transplantation, not at diagnosis. The Discussion describes an association, not evidence that the microbiome caused or influenced relapse. (LLM, conf=0.90)
plainstates an associationn = 541- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given these considerations, it is perhaps even more striking that bacteria generally associated with health (such as Clostridiales, Ruminococcacae, Faecalibacterium spp., Akkermansia muciniphila, B. fragilis,a n dBifidobacteria) (13, 14, 18-20) or immunogenicity (Enterococci, Collinsella, and Alistipes)( 11, 13, 14, 20) were found to be abundant in responding patients.”
What the sources say
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
In the paper’s discussion of Fig. 4, stools from one patient microbiome cluster promoted colonization by immunogenic B. fragilis and B. thetaiotaomicron, and mice receiving those stools responded to CTLA-4 blockade. The passage does not establish that these bacteria were more abundant in patients who responded to treatment; the reported treatment responses were in recipient mice. It also does not support the sentence’s full list of bacteria. (LLM, conf=0.87)
- Not checked yetcites [14] source
- Not checked yetcites [18] source
- Not checked yetcites [19]
- Supportedcites [20] source
The passage labeled Abstract reports that Enterococcus faecium and Collinsella aerofaciens were among eight species more abundant in responding patients. These support the immunogenic-bacteria portion of the cited sentence; the paper does not need to establish every organism listed alongside other citations. (LLM, conf=0.92)
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
The paper’s indexed text (labeled Abstract; page unavailable) reports that Alistipes correlated positively with TNF production and that giving A. shahii to mice restored a tumor-associated immune response. This supports an immunogenic role for Alistipes, but the study does not show that it—or the other named bacteria—was abundant in responding patients. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
33 more claims · 2 with their cited sources checked
Create a free account to see all 67 claims and to verify the 60 references still open.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Particularly, immune checkpoint inhibitory (ICI) therapy and adoptive cell therapy using tumor-specific CD8+ cytotoxic T lymphocytes (CTLs) can be influenced by the composition of the intestinal microbiota4,5.”
From Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the number of microbes that inhabit the human body (roughly equal to the number of human cells)”
From The microbiome and human cancer (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their gene count that exceeds the human genome’s gene count by ~100-fold and enables diverse metabolic programming”
From The microbiome and human cancer (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, following the epidemiological demonstration of the negative effect of antibiotics on the efficacy of ICIs13,42,90, specific microbial taxa have been associated with response or resistance to ICIs across distinct cancer types26,38–40,42,91–100.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“their effects on host immune system development and activity, including antitumor immunosurveillance (27–31).”
From The microbiome and human cancer (2021) · cites this paper as [30]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The gut microbiome and immuno-oncology
“immunotherapy through a combination of TLR9 antagonist and antibody to interleukin-10R (IL-10R) (11)”
§ The gut microbiome and immuno-oncology
“The immunizing effects of antibody to IL-10R + the TLR9 agonist CpG”
Citations
Cites
1 retracted
Lagier, J.-C., Khelaifia, S., Alou, M. T., Ndongo, S., Dione, N., Hugon, P., Caputo, A., Cadoret, F., Traore, S. I., Seck, E. H., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.203 · Cited by 951
Self-citationRetractedGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The gut microbiota shapes intestinal immune responses during health and disease
Round, J. L., & Mazmanian, S. K. (2009) · Nature Reviews Immunology · doi:10.1038/nri2515 · Cited by 5,029
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationInduction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Self-citationDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Cited by
Items 201–300 of 793
The Lung Microbiota and Lung Cancer: A Growing Relationship
Zerdan, M. B., Kassab, J. T., Meouchy, P., Haroun, E., Nehme, R., Zerdan, M. B., Fahed, G., Petrosino, M., Dutta, D., & Graziano, S. L. (2022) · Cancers · doi:10.3390/cancers14194813 · Cited by 49
“Intestinal dysbiosis, whether due to a disease or due to antibiotic use, may negatively affect the immunotherapeutic response [81,82].”
BackgroundInteraction between microbiota and immunity and its implication in colorectal cancer
Xing, C., Du, Y., Duan, T., Nim, K., Chu, J., Wang, H. Y., & Wang, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.963819 · Cited by 51
Łaniewski, P., Cui, H., Roe, D. J., Chase, D. M., & Herbst‐Kralovetz, M. M. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0126-x · Cited by 51
Current status and future perspectives of immunotherapy in bladder cancer treatment
Wu, Z., Liu, J., Dai, R., & Wu, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1768-y · Cited by 53
“Indeed, the efficacy of ICBs appears to be in close accordance with the patient’s gut microbiome in both mouse models (Vétizou et al., 2015) and humans (Zitvogel et al., 2018).”
ResultAssociation of the Microbiota and Pancreatic Cancer: Opportunities and Limitations
Chen, Z., Zhang, S., Dong, S., Xu, H., & Zhou, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844401 · Cited by 44
T-cell-based breast cancer immunotherapy
Pilipow, K., Darwich, A., & Losurdo, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.019 · Cited by 45
Pradhan, M., Chocry, M., Gibbons, D. L., Sepesi, B., & Cascone, T. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-573 · Cited by 48
“Accumulating evidence suggests that the composition of bacteria residing in the gut may play a key role in determining the efficacy of anticancer therapy, including ICIs (99,100).”
BackgroundThe role of the microbiome in drug resistance in gastrointestinal cancers
Garajová, I., Balsano, R., Wang, H., Leonardi, F., Giovannetti, E., Deng, D., & Peters, G. J. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1844007 · Cited by 50
The promise and perils of immunotherapy
Lesch, S., & Gill, S. I. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004453c · Cited by 47
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 45
“associated microbiome [103] were also associated with better response to ICB.”
BackgroundFrom hype to hope: Considerations in conducting robust microbiome science
McGuinness, A. J., Stinson, L. F., Snelson, M., Loughman, A., Stringer, A. M., Hannan, A. J., Cowan, C. S. M., Jama, H. A., Caparros-Martin, J. A., West, M. L., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.09.022 · Cited by 46
“Resident microbes can influence the bioavailability, and therefore the efficacy, of incoming therapeutics via direct and indirect mechanisms (Cussotto et al., 2021; Scher et al., 2020; Zitvogel et al., 2018).”
Detection of cell-free microbial DNA using a contaminant-controlled analysis framework
Zozaya‐Valdés, E., Wong, S. Q., Raleigh, J., Hatzimihalis, A., Ftouni, S., Papenfuss, A. T., Sandhu, S. K., Dawson, M. A., & Dawson, S. (2021) · Genome biology · doi:10.1186/s13059-021-02401-3 · Cited by 45
“Discussion In recent years, the role of the microbiome in cancer has been increasingly recognised, including its influence on response and toxicity to immunotherapy [5, 8, 9].”
BackgroundChen, N., Yu, Y., Shen, W., Xu, X., & Fan, Y. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.11.030 · Cited by 50
Park, I.-G., Yoon, S. J., Won, S., Oh, K., Hyun, J. Y., Suk, K. T., & Lee, U. (2024) · Scientific Reports · doi:10.1038/s41598-024-60768-2 · Cited by 44
Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
Olbryt, M., Rajczykowski, M., & Widłak, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114071 · Cited by 47
Predicting cancer immunotherapy response from gut microbiomes using machine learning models
Liang, H., Jo, J., Zhang, Z., MacGibeny, M. A., Han, J., Proctor, D. M., Taylor, M. E., Che, Y., Juneau, P. L., Apolo, A. B., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28252 · Cited by 50
Healthy Gut Microbiome Composition Enhances Disease Resistance and Fat Deposition in Tibetan Pigs
Shang, P., Wei, M., Duan, M., Yan, F., & Chamba, Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.965292 · Cited by 44
Benefits of using probiotics as adjuvants in anticancer therapy (Review)
Vivarelli, S., Falzone, L., Basile, M. S., Nicolosi, D., Genovese, C., Libra, M., & Salmeri, M. (2019) · World Academy of Sciences Journal · doi:10.3892/wasj.2019.13 · Cited by 57
“Repopulating the gut microbiota cancer of patients through the administration of probiotics, re-establishes both the abundance and the functionality of the commensal gut bacteria, which has been possibly depleted after the therapies (83).”
Immune checkpoint inhibitor–related luminal GI adverse events
Kröner, P. T., Mody, K., & Farraye, F. A. (2019) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2019.09.009 · Cited by 43
Daillère, R., Derosa, L., Bonvalet, M., Segata, N., Routy, B., Gariboldi, M., Budinská, E., De Vries, I. J. M., Naccarati, A. G., Zitvogel, V., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1774298 · Cited by 38
Self-citationBoesch, M., Horvath, L., Baty, F., Pircher, A., Wolf, D., Spahn, S., Straussman, R., Tilg, H., & Brutsche, M. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005401 · Cited by 38
Younas, A., Wang, S., Asad, M., Mamun, A. A., Majeed, S., Sharif, A., Zhou, Q., Liu, Y., Geng, P., Shao, C., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102660 · Cited by 75
“"Smart" nanoparticles are engineered with microbial enzyme-responsive linkers (e.g., azo-based polymers) for site-specific drug release in the gut or microbiome-rich tumors [146 – 148].”
Conducting metagenomic studies in microbiology and clinical research
Martin, T. C., Visconti, A., Spector, T. D., & Falchi, M. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9209-9 · Cited by 48
Wang, Z., Wang, Y., Fuhrman, J. A., Sun, F., & Zhu, S. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz025 · Cited by 55
“Previous studies have shown that microbiome composition is highly associated with human diseases [1–6], effectiveness of medical treatments [7–9], and functional changes in marine [10] and soil environments [11].”
BackgroundImmune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies
Yang, W., Lei, C., Song, S., Jing, W., Jin, C., Gong, S., Tian, H., & Guo, T. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02299-8 · Cited by 43
“Gut microbiome The diversity and composition of the intestinal flora have recently been found to significantly influence the efficacy of treatment with ICIs in oncology patients [78].”
BackgroundHuman Microbiota and Immunotherapy in Breast Cancer - A Review of Recent Developments
Vitorino, M. M., de Almeida, S. B., Costa, D. A., Faria, A., Calhau, C., & Braga, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.815772 · Cited by 47
The Role of Microbiota-Derived Vitamins in Immune Homeostasis and Enhancing Cancer Immunotherapy
Gholami, H., Chmiel, J. A., Burton, J. P., & Vareki, S. M. (2023) · Cancers · doi:10.3390/cancers15041300 · Cited by 43
Kim, J.-H., Kim, Y., La, J., Park, W. H., Kim, H.-J., Park, S. H., Ku, K. B., Kang, B. H., Lim, J., Kwon, M. S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113220 · Cited by 39
Modulation of Anti-Tumour Immune Responses by Probiotic Bacteria
Aindelis, G., & Chlichlia, K. (2020) · Vaccines · doi:10.3390/vaccines8020329 · Cited by 43
“Once there, they provide assistance to cytotoxic T cells, either through cytokine production or the induction of co-stimulatory signals [31].”
BackgroundRapoport, B. L., Shannon, V. R., Cooksley, T., Johnson, D. B., Anderson, L., Blidner, A. G., Tintinger, G. R., & Anderson, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.743582 · Cited by 44
Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer
Montégut, L., de Cabo, R., Zitvogel, L., & Kroemer, G. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0504 · Cited by 38
Self-citationZhang, C., Pi, X., Li, X., Huo, J., & Wang, W. (2024) · Food Chemistry · doi:10.1016/j.foodchem.2024.140267 · Cited by 44
Greathouse, K. L., & Choudhury, A. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.05.011 · Cited by 41
Microbiota-induced T cell plasticity enables immune-mediated tumour control
Najar, T. A., Hao, Y., Hao, Y., Romero‐Meza, G., Dolynuk, A., Almo, E., & Littman, D. R. (2026) · Nature · doi:10.1038/s41586-025-09913-z · Cited by 39
“Although specific bacterial taxa have been associated with favourable clinical responses to immune checkpoint blockade (ICB) in cancer patients 12,13,18–22 , the mechanisms by which the intestinal microbiota influences anti-tumour immune responses remain poorly defined.”
Gately, S. T. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_10 · Cited by 43
Global Analysis of Microbiota Signatures in Four Major Types of Gastrointestinal Cancer
Wang, J., Wang, Y., Li, Z., Gao, X., & Huang, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.685641 · Cited by 41
Carey, R. M., McMahon, D. B., Miller, Z. A., Kim, T., Rajasekaran, K., Gopallawa, I., Newman, J. G., Basu, D., Nead, K. T., White, E. A., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13131 · Cited by 38
Chen, F., Yang, J., Guo, Y., Su, D., Sheng, Y., & Wu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1140995 · Cited by 45
Gut microbiota, an emergent target to shape the efficiency of cancer therapy
Kouidhi, S., Zidi, O., Belkhiria, Z., Raïs, H., Ayadi, A., Ayed, F. B., Mosbah, A., Cherif, A., & Gaaied, A. B. A. E. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00132 · Cited by 39
“In fact, the administration of probiotics to cancer patients, mainly Lactobacilli, is to re-populate the altered patients’ gut microbiota, thus re-establishing the composition and functionality of the commensal bacteria [197].”
BackgroundHuman immune system: Exploring diversity across individuals and populations
Nguyen, K. H. H., Le, N. V., Nguyen, P., Nguyen, H. H. T., Hoang, D. M., & Huynh, C. D. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41836 · Cited by 50
Kaur, S., Thukral, S. K., Kaur, P., & Samota, M. K. (2021) · Future Foods · doi:10.1016/j.fufo.2021.100043 · Cited by 41
Pro- and Anti- Effects of Immunoglobulin A- Producing B Cell in Tumors and Its Triggers
Zhong, Z., Nan, K., Weng, M., Yue, Y., Zhou, W., Wang, Z., Chu, Y., Liu, R., & Miao, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765044 · Cited by 42
Jiang, M., Yang, Z., Dai, J., Wu, T., Jiao, Z., Yu, Y., Kang, N., Chen, W., & Yang, A. (2023) · MedComm · doi:10.1002/mco2.376 · Cited by 39
Ichim, T. E., Kesari, S., & Shafer, K. (2018) · Oncotarget · doi:10.18632/oncotarget.25778 · Cited by 40
“Also, in a study of the anti-cancer effects of anti-PD1 or anti-PD-L1 checkpoint inhibitor antibodies, Bifidobacteria, a common probiotic strain, were found to be abundant in the colons of experimental animals that exhibited effective immunity against melanoma [15].”
BackgroundMicrobiota: Overview and Implication in Immunotherapy-Based Cancer Treatments
Brandi, G., & Frega, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112699 · Cited by 37
“Plausible strategies to fine-tune the microbiota encompass dietary refinement, avoiding improper use of antibiotics, fecal microbial transplantations, and the administrations of prebiotics/probiotics [19,108].”
BackgroundInfluentialCancer Genomics in Precision Oncology: Applications, Challenges, and Prospects
Pereira, M. A., Kunrath‐Lima, M., Couto, P. G. P., Penna, M. G., Alvim, L. B., Nani, T. F., Freire, M. C. M., & Araujo, L. H. (2020) · Springer eBooks · doi:10.1007/978-981-15-1067-0_21 · Cited by 47
Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
dos Santos, L. V., Abrahão, C. M., & William, W. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.596290 · Cited by 42
Advances in immunotherapy for MMR proficient colorectal cancer
Lote, H., Starling, N., Pihlak, R., & Gerlinger, M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102480 · Cited by 38
Integrative systems biology approaches for analyzing microbiome dysbiosis and species interactions
Rehman, S. S. U., Nasar, M. I., Mesquita, C. S., Khodor, S. A., Notebaart, R. A., Ott, S., Mundra, S., Arasardanam, R. P., Muhammad, K., & Alam, M. T. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf323 · Cited by 36
“[164] for more details.”
Mediation effect selection in high‐dimensional and compositional microbiome data
Zhang, H., Chen, J., Feng, Y., Wang, C., Li, H., & Liu, L. (2020) · Statistics in Medicine · doi:10.1002/sim.8808 · Cited by 40
“Step 1: Sort the P-values {Praw,l}l=1 in (6) as Praw,r1 ≤ Praw,r2 ≤ · · · ≤ Praw,rd .”
MethodInfluentialMicrobial dysbiosis and epigenetics modulation in cancer development – A chemopreventive approach
Haque, S., Raina, R., Afroze, N., Hussain, A., Alsulimani, A., Singh, V., Mishra, B. N., Kaul, S., & Kharwar, R. N. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.024 · Cited by 37
The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer
Rahman, R. A., Lamarca, Á., Hubner, R. A., Valle, J. W., & McNamara, M. G. (2021) · Cancers · doi:10.3390/cancers13153779 · Cited by 36
Gut Microbiome in Health and Disease
Lavelle, A., & Hill, C. (2019) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.02.003 · Cited by 40
Advances in theranostic biomarkers for tumor immunotherapy
Bellesœur, A., Torossian, N., Amigorena, S., & Romano, E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.005 · Cited by 35
Emerging role of microbiota in immunomodulation and cancer immunotherapy
Singh, R. P., Bashir, H., & Kumar, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.008 · Cited by 35
Sepich‐Poore, G. D., Guccione, C., Laplane, L., Pradeu, T., Curtius, K., & Knight, R. (2022) · BioEssays · doi:10.1002/bies.202100252 · Cited by 33
Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
Terrisse, S. A., Zitvogel, L., & Kroemer, G. (2022) · Microbial Cell · doi:10.15698/mic2022.12.787 · Cited by 38
“As true for other cancers treated by immunogenic chemotherapy or immunotherapy [1, 2, 3, 4], the gut microbiota plays a major role in determining the therapyrelevant immune response elicited by ADT against PC.”
Self-citationDóra, D., Szőcs, E., Soós, Á., Halasy, V., Somodi, C., Mihucz, A., Rostás, M., Mógor, F., Lohinai, Z., & Nagy, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1434804 · Cited by 34
“…and 16S rRNA sequencing are used to determine the bacterial signatures observed in the stool samples of responder and non-responder patients (360) that can further provide us information about the intra-sample variability (alpha diversity) and between-sample variability (beta diversity) of…”
Mucosal cancer-associated microbes and anastomotic leakage after resection of colorectal carcinoma
Mima, K., Sakamoto, Y., Kosumi, K., Ogata, Y., Miyake, K., Hiyoshi, Y., Ishimoto, T., Iwatsuki, M., Baba, Y., Iwagami, S., et al. (2019) · Surgical Oncology · doi:10.1016/j.suronc.2019.11.005 · Cited by 35
Strategies to overcome resistance to immune checkpoint blockade in lung cancer
Attili, I., Tarantino, P., Passaro, A., Stati, V., Curigliano, G., & de Marinis, F. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.035 · Cited by 34
Influence of Microbiota on Tumor Immunotherapy
Yu, X., Li, W., Li, Z., Wu, Q., & Sun, S. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91771 · Cited by 37
“One intriguing aspect contributing to the progress in tumor immunotherapy is the historical findings related to the impact of bacteria on this therapeutic approach [16].”
BackgroundSomodi, C., Dóra, D., Horváth, M., Szegvári, G., & Lohinai, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06586-0 · Cited by 40
Microbiome and host crosstalk: A new paradigm to cancer therapy
Singh, A. K., Nayak, N., Rathi, P., Verma, D., Sharma, R., Chaudhary, A., Agarwal, A., Tripathi, Y. B., & Garg, N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.014 · Cited by 35
Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy
Ocáriz, M., Cruellas, M., Ruiz, M. G., Lastra, R. P., Martínez‐Lostao, L., Ramírez-Labrada, A., Paño, J. R., Sesma, A., Torres, I., Yubero, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568939 · Cited by 34
Xin, Y., Liu, C., Zang, D., & Chen, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343450 · Cited by 39
Urobiome in Gender—Related Diversities of Bladder Cancer
Bilski, K., Dobruch, J. T., Kozikowski, M., Skrzypczyk, M., Oszczudłowski, M., & Ostrowski, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124488 · Cited by 33
Gut microbiota reshapes the TNBC immune microenvironment: Emerging immunotherapeutic strategies
Huang, M., Zhang, Y., Chen, Z., Yu, X., Luo, S., Peng, X., & Li, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107726 · Cited by 34
Ebrahim, N. A. A., Soliman, S. M. A., Othman, M. O., & Tahoun, N. S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02729-x · Cited by 32
“Moreover, system-wide metabolic disruptions could have unintended systemic effects, making precision targeting a significant challenge [119].”
Engineering nanoplatforms of bacterial outer membrane vesicles to overcome cancer therapy resistance
Chai, Q., Li, D., Zhang, M., Gu, Y., Li, A., Wu, X., Liu, X., & Liu, J. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101277 · Cited by 36
Alagna, L., Palomba, E., Mangioni, D., Bozzi, G., Lombardi, A., Ungaro, R., Castelli, V., Prati, D., Vecchi, M. L., Muscatello, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165619 · Cited by 35
“There is growing evidence within the various fields of application of FMT (ranging from CDI and MDR decolonization to autoimmune and chronic bowel disease treatment, to cancer immunotherapy [82]) that there exist individuals whose stools are associated with significantly more successful FMT outcomes [83].”
BackgroundExploring the food-gut axis in immunotherapy response of cancer patients
Russo, E., Nannini, G., Dinu, M., Pagliai, G., Sofi, F., & Amedei, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i33.4919 · Cited by 32
The Microbiome and Its Implications in Cancer Immunotherapy
Choudhry, H. (2021) · Molecules · doi:10.3390/molecules26010206 · Cited by 31
Redrawing therapeutic boundaries: microbiota and cancer
Sholl, J., Sepich‐Poore, G. D., Knight, R. D., & Pradeu, T. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.008 · Cited by 33
Microbiota, a Third Player in the Host–Plasmodium Affair
Mukherjee, D., Chora, Â. F., & Mota, M. M. (2019) · Trends in Parasitology · doi:10.1016/j.pt.2019.11.001 · Cited by 33
Predictive biomarkers of response to immune checkpoint inhibitors in melanoma
Nebhan, C. A., & Johnson, D. B. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1724539 · Cited by 32
“Higher gastrointestinal microbiodiversity is associated with positive response to ICI [54].”
BackgroundApplying artificial intelligence in the microbiome for gastrointestinal diseases: A review
Zeng, T., Yu, X., & Chen, Z. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15503 · Cited by 34
“84 As an example of preventive medicine, mobile cloud-based electrocardiograph monitoring and analysis has been developed to meet the demand for portable solutions supporting personalized medical diagnosis and treatment.”
BackgroundThe microbiome of HPV-positive tonsil squamous cell carcinoma and neck metastasis
Rajasekaran, K., Carey, R. M., Lin, X., Seckar, T. D., Wei, Z., Chorath, K. T., Newman, J. G., O'Malley, B. W., Weinstein, G. S., Feldman, M. D., et al. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105305 · Cited by 31
Löwenmark, T., Löfgren‐Burström, A., Zingmark, C., Ljuslinder, I., Dahlberg, M. L., Edin, S., & Palmqvist, R. (2022) · Cancers · doi:10.3390/cancers14235937 · Cited by 30
“Indeed, recent studies have suggested that the intestinal microecological composition is related to CRC prognosis [2] and specific gut microbial species have been associated with a deteriorated response to cancer therapy [6].”
BackgroundRepertoire of Bacterial Species Cultured from the Human Oral Cavity and Respiratory Tract
Fonkou, M. D. M., Dufour, J.-C., Dubourg, G., & Raoult, D. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0181 · Cited by 33
Self-citationImmunodivergence in Metastatic Colorectal Cancer
de Andrea, C. E., Schalper, K. A., Sanmamed, M. F., & Melero, I. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.012 · Cited by 34
Mao, J., Zhang, S., Du, P., Cheng, Z., Hu, H., & Wang, S. (2020) · Journal of Immunology Research · doi:10.1155/2020/4092472 · Cited by 30
Kattar, S. A., Jurjus, R. A., Pinon, A., Leger, D. Y., Jurjus, A. R., Boukarim, C., Diab‐Assaf, M., & Liagre, B. (2020) · Cancers · doi:10.3390/cancers12071857 · Cited by 34
Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review
Petrelli, F., Ghidini, A., Dottorini, L., Ghidini, M., Zaniboni, A., & Tomasello, G. (2025) · Medicina · doi:10.3390/medicina61091595 · Cited by 33
Effect of bacterial contamination in bile on pancreatic cancer cell survival
Shrader, H. R., Miller, A. M., Tomanek‐Chalkley, A., McCarthy, A., Coleman, K. L., Ear, P. H., Mangalam, A. K., Salem, A. K., & Chan, C. H. F. (2020) · Surgery · doi:10.1016/j.surg.2020.09.029 · Cited by 32
The intratumoural microbiota in cancer: new insights from inside
An, Y., Zhang, W., Liu, T., Wang, B., & Cao, H. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188626 · Cited by 29
The Roles of the Virome in Cancer
Broecker, F., & Moelling, K. (2021) · Microorganisms · doi:10.3390/microorganisms9122538 · Cited by 34
“Germ-free or antibiotic-treated mice with depleted intestinal bacteria serve as animal models for the effects of the microbiota of responders and non-responders [103].”
BackgroundLöwenmark, T., Li, X., Löfgren‐Burström, A., Zingmark, C., Ling, A., Kellgren, T. G., Larsson, P. G., Ljuslinder, I., Wai, S. N., Edin, S., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03179-4 · Cited by 30
Microbiota Regulates Pancreatic Cancer Carcinogenesis through Altered Immune Response
Chai, Y., Huang, Z., Shen, X., Lin, T., Zhang, Y., Xu, F., Mao, Q., & Liang, Y. (2023) · Microorganisms · doi:10.3390/microorganisms11051240 · Cited by 29
Tak, U., Schinkel, K., Walth, P., Tay, J. W., Hartwick, E. W., & Whiteley, A. T. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.03.004 · Cited by 32
Gomes, A., Oudot, C., Macià, A., Foito, A., Carregosa, D., Stewart, D., de Wiele, T. V., Berry, D., Motilva, M., Brenner, C., et al. (2019) · Nutrients · doi:10.3390/nu11112634 · Cited by 32
“Moreover, there is increasing evidence that the activity and composition of the gut microbiota is implicated in many disease states, particularly in CVDs, in response to treatment [50].”
BackgroundInosine: novel microbiota-derived immunostimulatory metabolite
Kroemer, G., & Zitvogel, L. (2020) · Cell Research · doi:10.1038/s41422-020-00417-1 · Cited by 28
Self-citationKirishima, M., Yokoyama, S., Matsuo, K., Hamada, T., Shimokawa, M., Akahane, T., Sugimoto, T., Tsurumaru, H., Ishibashi, M., Mataki, Y., et al. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02557-3 · Cited by 29
“The gut microbiota is increasingly considered an important factor associated with both tumor development and the efficacy of anticancer therapies [15, 16].”
BackgroundThe role of gut microbiota in the development of colorectal cancer: a review
Koyande, N. P., Gangopadhyay, M., Thatikonda, S., & Rengan, A. K. (2022) · International Journal of Colorectal Disease · doi:10.1007/s00384-022-04192-w · Cited by 30
“The gut microbiota and its metabolites can also activate the immune system by triggering T-cell responses leading to anticancer effects; this approach can be used in tumor immunotherapy [116, 117].”
BackgroundMiya, T. V., Marima, R. M., Damane, B. P., Ledet, E. M., & Dlamini, Z. (2023) · Cancers · doi:10.3390/cancers15164086 · Cited by 33
“State-of-the-art techniques have shown that microbiota influence carcinogenesis and immunotherapy [109].”
BackgroundMicrobiota intestinal: el órgano olvidado
Rivera, J. A. M., Pacheco, S. T., Greene, E. J. D., & Weber, F. L. R. (2021) · Acta Médica Grupo Ángeles · doi:10.35366/98577 · Cited by 38
Hogue, S., Gómez, M. F. L., da Silva, W. V., & Pierce, C. M. (2019) · Microbial Ecology · doi:10.1007/s00248-019-01346-2 · Cited by 27
Drug–Microbiota Interaction in Colon Cancer Therapy: Impact of Antibiotics
Mohamed, A. A., Menon, H., Chulkina, M., Yee, N. S., & Pinchuk, I. V. (2021) · Biomedicines · doi:10.3390/biomedicines9030259 · Cited by 27
“Potential environmental modulators of the gut microbiome composition include antibiotics, diet, use of pre-/probiotics, exercise and sleep cycles [57].”
BackgroundIntratumoral bacteria generate a new class of therapeutically relevant tumor antigens in melanoma
Sepich‐Poore, G. D., Carter, H. K., & Knight, R. D. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.008 · Cited by 30
Li, J., Zhang, Y., Cai, Y., Yao, P., Jia, Y., Wei, X., Du, C., & Zhang, S. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04104-23 · Cited by 33
Haakensen, V. D., Nowak, A. K., Ellingsen, E. B., Farooqi, S. J., Bjaanæs, M. M., Horndalsveen, H., McCulloch, T., Grundberg, O., Cedrés, S., & Helland, Å. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02905-3 · Cited by 30
Metadata
- Authors
- Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F.
- Affiliations
- Université Paris-Sud (FR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Centre National de la Recherche Scientifique (FR)
- Sorbonne Paris Cité (FR)
- University of Chicago (US)
- Corresponding author
- Zitvogel, Laurence
- Gajewski, Thomas F.
- Venue
- Science
- Published
- 2018-03-23
- Volume
- 359
- Issue
- 6382
- Pages
- 1366-1370
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2791926234
- Cited by
- 777
- References
- 74
- Citations by year
- 2026: 84 · 2025: 85 · 2024: 74 · 2023: 96 · 2022: 84 · 2021: 130 · 2020: 105 · 2019: 81 · 2018: 37
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Melanoma Research Alliance (CA210098)
- University of Chicago (T32 CA009594)
- Association pour la Recherche sur le Cancer
- Seerave Foundation
- Jounce Therapeutics
- Incyte
- E-Rare
- European Commission
- Agence Nationale de la Recherche (ANR-10-LABX-0015)
- Fondation Leducq
- National Natural Science Foundation of China (81671630, CAMS-I2M, 2017YFA0506200, 81722037)
- Fondation pour la Recherche Médicale
- Government of Jiangsu Province
- Ligue Contre le Cancer
- Natural Science Foundation of Jiangsu Province (BK20170006, BK20160379)
- Institut Universitaire de France
- Chinese Academy of Medical Sciences (2016‐I2M‐1‐005, (CAMS-I2M), 2017RC31008, 2017NL31004, 2016ZX310194)
- Institut National Du Cancer
- Institut Gustave-Roussy
- Recruitment Program of Global Experts
- Genentech
- University of Chicago Medicine
- National Key Research and Development Program of China (2017YFA0506200)
- Labex Immuno-Oncology
- Comprehensive Cancer Center, University of Chicago Medical Center (T32 CA009594)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- gut microbiota, cancer immunotherapy, immune checkpoint inhibitors, host-microbe interactions, precision medicine, microbiome-based diagnostics, microbiota-based therapy, cancer immunotherapy resistance
- MeSH terms
- Gastrointestinal Microbiome, Humans, Immune System, Immunotherapy, Neoplasms, Treatment Outcome, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.